Alterations of the intestinal barrier in patients with autism spectrum disorders and in their first-degree relatives

Journal of Pediatric Gastroenterology and Nutrition

Volumn 51, Issue 4, 2010, Pages 418-424

  De Magistris, Laura ^a,c   Familiari, Valeria ^a   Pascotto, Antonio ^b,f   Sapone, Anna ^a   Frolli, Alessandro ^b   Iardino, Patrizia ^c   Carteni, Maria ^b   De Rosa, Mario ^b   Francavilla, Ruggiero ^e   Riegler, Gabriele ^a   Militerni, Roberto ^b   Bravaccio, Carmela ^d  

^a Gastroenterology Unit   (Italy)

^b Department of Psychiatry Neuropsychiatry Dermatovenereology ^*  (Italy)

^c SECOND UNIVERSITY OF NAPLES   (Italy)

^d UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^e UNIVERSITY OF BARI   (Italy)

^f Fondazione Istituto Antoniano   (Italy)

Author keywords

Autism; Calprotectin; First degree relatives; Gastrointestinal symptoms; Intestinal permeability

Indexed keywords

CALGRANULIN; CASEIN; LACTULOSE; MANNITOL;

ABDOMINAL PAIN; ARTICLE; AUTISM; CHILD; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; FECES ANALYSIS; FEMALE; GLUTEN FREE DIET; HUMAN; INTESTINE MUCOSA PERMEABILITY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ABDOMINAL PAIN; ANALYSIS OF VARIANCE; CHILD; CHILD DEVELOPMENT DISORDERS, PERVASIVE; COMORBIDITY; CONSTIPATION; DIARRHEA; ENZYME-LINKED IMMUNOSORBENT ASSAY; FAMILY; FECES; FEMALE; HUMANS; INFLAMMATION; INTESTINAL DISEASES; INTESTINAL MUCOSA; ITALY; LEUKOCYTE L1 ANTIGEN COMPLEX; MALE; PERMEABILITY;

EID: 78449231774     PISSN: 02772116     EISSN: None     Source Type: Journal    
DOI: 10.1097/MPG.0b013e3181dcc4a5     Document Type: Article

References (51)

1. White JF. Intestinal pathophysiology in autism. Exp Biol Med 2003; 228: 639-49.
2. Erickson CA, Stigler KA, Corkins MR, et al. Gastrointestinal factors in autistic disorder: A critical review. J Autism Dev Disord 2005; 35: 713-27.
3. Jass JR. The intestinal lesion of autistic spectrum disorder. Eur J Gastroenterol Hepatol 2005;17: 821-2.
4. Liu Z, Li N, Neu J. Tight junctions, leaky intestines, and paediatric diseases. Acta Paediatr 2005;94: 386-93.
5. Buie T, Campbell DB, Fuchs GJ, et al. Evaluation, diagnosis, and treatment of gastrointestinal disorders in individuals with ASDs: A consensus report. Pediatrics 2010;125(Suppl 1): S1-8.
6. Levy SE, Souders MC, Ittenbach RF, et al. Relationship between dietary intake and gastrointestinal symptoms in children with autistic spectrum disorders. Biol Psychiatry 2007;61: 492-7.
7. Nikolov RN, Bearss KE, Lettiga J, et al. Gastrointestinal symptoms in a sample of children with pervasive developmental disorders. J Autism Dev Disord 2008;39: 405-13.
8. Wei J, Hemmings GP. Gene, gut and schizophrenia: The meeting point for the gene-environment interaction in developing schizophrenia. Med Hypotheses 2005;64: 547-52.
9. Cascella NG, Kryszak D, Bhatti B, et al. Prevalence of celiac disease and gluten sensitivity in the United States clinical antipsychotic trials of intervention effectiveness study population. Schizophr Bull [e-pub ahead of print June 3, 2009].
10. Wakefield AJ, Ashwood P, Limb K, et al. The significance of ileocolonic lymphoid nodular hyperplasia in children with autistic spectrum disorder. Eur J Gastroenterol Hepatol 2005;17: 827-36.
11. MacDonald TT, Domizio P. Autistic enterocolitis; is it a histopathological entity? Histopathology 2007;50: 371-9.
12. MacDonald TT. The significance of ileocolonic lymphoid nodular hyperplasia in children with autistic spectrum disorders. Eur J Gastroenterol Hepatol 2006;18: 569-73.
13. Turck D, Michaud L. Lower gastrointestinal bleeding. In: Kleinman RE, Goulet O-J, Mieli-Vergani G, et al. eds. Walker's Pediatric Gastroenterologic Diseases: Pathophysiology,Diagnosis,Management. Section 6, Vol 2, 5th ed. Hamilton, Canada: BC Decker; 2008: Chap 46.3b.
14. D'Eufemia P, Celli M, Finocchiaro R, et al. Abnormal intestinal permeability in children with autism. Acta Paediatr 1996;85: 1076-9.
15. Shattock P, Whiteley P. Biochemical aspects in autism spectrum disorders: Updating the opioid-excess theory and presenting new opportunities for biochemical intervention. Expert Opin Ther Targets 2002;6: 175-83.
16. Bjarnason I, MacPherson A, Hollander D. Intestinal permeability: An overview. Gastroenterology 1995;108: 1566-81.
17. Watts T, Berti I, Sapone A, et al. Role of the intestinal tight junction modulator zonulin in the pathogenesis of type-1 diabetes in BB diabetic prone rats. Proc Natl Acad Sci U S A 2005;102: 2016-21.
18. Munkholm P, Langholz E, Hollander D, et al. Intestinal permeability in patients with Crohn's disease and ulcerative colitis and their first degree relatives. Gut 1994;35: 68-72.
19. Peeters M, Geypens B, Claus D, et al. Clustering of increased small intestinal permeability in families with Crohn's disease. Gastroenterology 1997;113: 802-7.
20. Secondulfo M, deMagistris L, Fiandra R, et al. Intestinal permeability in Crohn's disease patients and their first degree relatives. Digest Liver Dis 2001;33: 680-5.
21. Robertson MA, Sigalet DL, Holst JJ, et al. Intestinal permeability and glucagon-like peptide-2 in children with autism: A controlled pilot study. J Autism Dev Disord 2008;38: 1066-71.
22. Roseth AG, Aadland E, Jahnsen J, et al. Assessment of disease activity in ulcerative colitis by faecal calprotectin, a novel granulocyte marker protein. Digestion 1997;58: 176-80.
23. Lord C, Rutter M, LeCouteur A. Autism Diagnostic Interview-Revised: A revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders. J Autism Dev Disord 1994;24: 659-85.
24. Shopler E, Reichler RJ, DeVellis RF, et al. Toward objective classification of childhood autism: Childhood Autism Rating Scale (CARS). J Autism Dev Disord 1980;10: 91-103.
25. DiLavore PC, Lord C, Rutter M. The pre-linguistic autism diagnostic observation schedule. J Autism Dev Disord 1995;25: 355-79.
26. Generoso M, De Rosa M, De Rosa R, et al. Cellobiose and lactulose coupled with mannitol and determined using ion-exchange chromatography with pulsed amperometric detection, are reliable probes for the investigation of intestinal permeability. J Chromatogr B Analyt Technol Biomed Life Sci 2003;783: 349-57.
27. Secondulfo M, Iafusco D, Carratù R, et al. Ultrastructural mucosal alterations and increased intestinal permeability in non-celiac, type 1 diabetic patients. Digest Liver Dis 2004;225: 1-11.
28. Roseth AG, Fagerhol MK, Aadland E, et al. Assessment of the neutrophil dominating protein calprotectin in feces: A methodological study. Scand J Gastroenterol 1992;27: 793-8.
29. Berni Canani R, Rapacciuolo L, Romano MT, et al. Diagnostic value of faecal calprotectin in paediatric gastroenterology clinical practice. Dig Liver Dis 2004;36: 467-70.
30. Bunn SK, Bisset WM, Main MJ, et al. Fecal calprotectin: Validation as a non-invasive measure of bowel inflammation in childhood inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2001;33: 11-3.
31. Clemente MG, DeVirgiliis S, Kang JS, et al. Early effects of gliadin on enterocyte intracellular signalling involved in intestinal barrier function. Gut 2003;52: 218-23.
32. Dolfini E, Roncoroni L, Elli L, et al. Cytoskeleton reorganization and ultrastructural damage induced by gliadin in a three-dimensional in vitro model. World J Gastroenterol 2005;11: 7597-601.
33. Thomas KE, Sapone A, Fasano A, et al. Gliadin stimulation of murine macrophage inflammatory gene expression and intestinal permeability are MyD88-dependent: Role of the innate immune response in celiac disease. J Immunol 2006;176: 2512-21.
34. Bodinier M, Legoux MA, Pineau F, et al. Intestinal translocation capabilities of wheat allergens using the Caco-2 cell line. J Agric Food Chem 2007;55: 4576-83.
35. Lammers KM, Lu R, Brownley J, et al. Gliadin induces an increase in intestinal permeability and zonulin release by binding to the chemokine receptor CXCR3. Gastroenterology 2008;135: 194-204.
36. Sapone A, Lammers KM, Mazzarella G, et al. Differential mucosal IL-17 expression in two gliadin-induced disorders: Gluten sensitivity and the autoimmune enteropathy celiac disease. Int Arch Allergy Immunol 2009;152: 75-80.
37. Visser J, Rozing J, Sapone A, et al. Tight junctions, intestinal permeability, and autoimmunity: Celiac disease and type 1 diabetes paradigms. Ann N Y Acad Sci 2009;1165: 195-205.
38. Natividad JM, Huang X, Slack E, et al. Host responses to intestinal microbial antigens in gluten-sensitive mice. PLoS One 2009;4: E6472.
39. Knivsberg AM, Reichelt KL, Hoien T, et al. A randomised, controlled study of dietary intervention in autistic syndromes. Nutr Neurosci 2002;5: 251-61.
40. Millward C, Ferriter M, Calver S, et al. Gluten- and casein-free diets for autistic spectrum disorder. Cochrane Database Syst Rev 2008;2: CD003498.
41. Murch S. Diet, immunity, and autistic spectrum disorders. J Pediatr 2005;146: 582-4.
42. Iacono G, Ravelli A, DiPrima L, et al. Colonic lymphoid nodular hyperplasia in children: Relationship to food hypersensitivity. Clin Gastroenterol Hepatol 2007;5: 361-6.
43. Wakefield AJ, Puleston JM, Montgomery SM, et al. The concept of entero-colonic encephalopathy, autism and opioid receptor ligands. Aliment Pharmacol Ther 2002;16: 663-74.
44. Pavone L, Fiumara A, Bottaro G, et al. Autism and celiac disease: Failure to validate the hypothesis that a link might exist. Biol Psychiatry 1997;42: 72-5.
45. Genuis SJ, Bouchard TP. Celiac disease presenting as autism. J Child Neurol 2010;25: 114-9.
46. Hollander D. The intestinal permeability barrier. A hypothesis as to its regulation and involvement in Crohn's disease. Scand J Gastroenterol 1992;27: 721-6.
47. Troncone R, Caputo N, Micillo M, et al. Immunologic and intestinal permeability tests as predictors of relapse during gluten challenge in childhood celiac disease. Scand J Gastroenterol 1994;29: 144-7.
48. Husebye E, Ton H, Johne B. Biological variability of fecal calprotectin in patients referred for colonscopy without colonic inflammation or neoplasm. Am J Gastroenterol 2001;96: 2683-7.
49. Shulman RJ, Eakin MN, Czyzewski DI, et al. Increased gastrointestinal permeability and gut inflammation in children with functional abdominal pain and irritable bowel syndrome. J Pediatr 2008;153: 646-50.
50. Tibble JA, Sigthorsson G, Foster R, et al. Use of surrogate markers of inflammation and Rome criteria to distinguish organic from non-organic intestinal disease. Gastroenterology 2002;123: 450-60.
51. Tripathi A, Lammers KM, Goldblum S, et al. Identification of human zonulin, a physiological modulator of tight junctions, as prehapto globin-2. Proc Natl Acad Sci U S A 2009;106: 16799-804.